Eli Lilly, Sitryx sign potential $880m deal to develop immunometabolic medicines

Eli Lilly has entered into a potential $880m research deal with Sitryx to discover and develop new immunometabolic medicines. Under an exclusive global licensing and research collaboration, the companies will involve in the assessment of up to four novel preclinical targets detected by Sitryx. The new targets may help develop potential new medicines for autoimmune diseases. Lilly immunology vice president Dr Ajay Nirula said: “As Lilly seeks to develop new and unique medicines for people suffering with autoimmune diseases, we are actively exploring a variety of scientific approaches both in our own labs and with external partners.”